Keytruda (Pembrolizumab): Availability, Dosing, Cost & How to Find It in Stock

Keytruda is one of the most important cancer medications of the last decade — and also one of the more challenging prescriptions to locate at a retail pharmacy. This guide covers everything you need to know: how it works, what it costs, who can prescribe it, and most importantly, how to find it when your pharmacy doesn't have it in stock.

What Is Keytruda?

Keytruda is the brand name for pembrolizumab, a monoclonal antibody that belongs to a class of cancer treatments called PD-1 inhibitors (more on what that means in the next section). It was first approved by the FDA in September 2014, making it one of the earliest checkpoint inhibitors to reach U.S. patients. Since that initial approval for advanced melanoma, Keytruda has expanded to become one of the most broadly approved cancer drugs in history — with FDA indications now covering more than 30 different tumor types, including non-small cell lung cancer, head and neck cancer, bladder cancer, colorectal cancer, gastric cancer, cervical cancer, triple-negative breast cancer, hepatocellular carcinoma, and several others.

Keytruda is prescribed to a wide range of patients, from adults with early-stage cancers to those with advanced or metastatic disease. It's used both as a standalone therapy and in combination with chemotherapy, targeted therapy, or other immunotherapy agents, depending on the cancer type and stage. In some indications, it's used as a first-line treatment — meaning it's given before other therapies are tried. In others, it steps in when standard treatments haven't worked. Your oncologist will determine where Keytruda fits in your specific treatment plan based on your tumor's biomarkers (particularly PD-L1 expression and microsatellite instability status), your overall health, and the current treatment guidelines for your cancer type.

As of now, Keytruda remains a brand-name-only medication manufactured by Merck. There is no FDA-approved generic version of pembrolizumab currently available in the United States, though biosimilar development is underway in the industry. Because it is a biologic — a large, complex molecule produced in living cells rather than a simple chemical synthesis — the pathway to generic (biosimilar) approval is more involved than for traditional drugs. This brand-only status has significant implications for cost and availability. If you're having trouble finding Keytruda, FindUrMeds can locate it at a pharmacy near you.

How Does Keytruda Work?

Your immune system has natural "checkpoints" — molecular off-switches that prevent it from going into overdrive and attacking healthy tissue. One of the most important checkpoints involves a protein on your T-cells called PD-1 (programmed death-1). Under normal circumstances, when PD-1 connects with its partner protein PD-L1 (found on normal cells), it tells your immune cells to stand down. Cancer cells are clever: many tumors overexpress PD-L1 specifically to hijack this system and hide from your immune system. Keytruda works by blocking PD-1, essentially removing the "do not attack" signal. With that checkpoint disengaged, your T-cells can recognize cancer cells as foreign and mount an attack against them. This is why it's called an immune checkpoint inhibitor — it lifts the brakes off your own immune system rather than directly killing cancer cells the way traditional chemotherapy does.

Keytruda is administered as an intravenous (IV) infusion, delivered directly into a vein over approximately 30 minutes. It is not a pill or a self-injection you take at home — infusions are given in a clinical setting such as an oncology infusion center or hospital. Dosing frequency depends on your regimen: the standard adult doses are 200 mg every 3 weeks or 400 mg every 6 weeks. Some patients begin noticing treatment response within 8–12 weeks, though clinical responses can continue to develop over months. The duration of treatment varies widely — some patients receive Keytruda for up to 2 years; others continue longer depending on response and tolerability. Because it's a long-acting immunotherapy rather than a short-course drug, consistent availability of supply is critical for uninterrupted treatment.

Available Doses of Keytruda

Keytruda is available in the following FDA-approved formulations:

Keytruda 25 mg/mL concentration — 4 mL vial (100 mg total): The most widely used vial size, standard for the 200 mg dose (2 vials per infusion)
Keytruda 25 mg/mL concentration — 16 mL vial (400 mg total): Used for the every-6-weeks dosing schedule
Keytruda for injection, lyophilized powder — 50 mg per vial: Less commonly encountered at retail pharmacies; typically used in specific institutional settings

The most common starting dose for adults is 200 mg administered intravenously every 3 weeks. Some treatment protocols use the flat dose of 400 mg every 6 weeks, which is pharmacokinetically equivalent and can be more convenient for patients. Pediatric dosing (for eligible indications) is typically weight-based at 2 mg/kg (up to 200 mg) every 3 weeks. Your oncologist and infusion center will determine the exact vial configuration needed for your regimen.

Having trouble finding a specific dose? FindUrMeds searches all strengths simultaneously.

Keytruda Findability Score

Keytruda Findability Score: 28 out of 100 (Scale: 1 = hardest to find, 100 = easiest)

Our Findability Score is a proprietary metric that reflects how difficult a medication is to locate in stock at U.S. retail and specialty pharmacies on any given day. The score pulls from our platform's data across 15,000+ pharmacy locations, accounting for factors like drug class, distribution channel, shortage history, storage requirements, prescribing volume, and regional availability patterns. A score of 28 puts Keytruda in the "challenging to find" tier — not impossible, but significantly harder than a typical retail prescription, and harder than the average specialty medication.

So why does Keytruda score a 28? Several compounding factors are at play. First, pembrolizumab is a biologic medication that requires specialty pharmacy distribution — it doesn't sit on shelves at your local CVS or Walgreens the way a statin or antibiotic does. The vast majority of Keytruda doses are dispensed through specialty pharmacies, hospital pharmacies, and oncology infusion centers that order directly from Merck's specialty distributor network. Second, Keytruda requires refrigerated storage at 2°C to 8°C (36°F to 46°F) and must be protected from light — not every pharmacy has the cold-chain infrastructure to stock biologics at this level. Third, while Keytruda has not appeared on the FDA's formal Drug Shortage Database as a nationwide shortage drug at the time of this writing, our platform's analysis of Keytruda availability found localized and regional supply tightness, particularly at independent and mid-size pharmacies, that can make fulfillment unpredictable for patients who aren't already established at a specialty pharmacy. According to our data across more than 40,000 pharmacy searches for oncology biologics, specialty medications like pembrolizumab are typically stocked at only 8–12% of general retail pharmacy locations in any given metro area.

For patients, this means that showing up at a standard retail pharmacy with a Keytruda prescription — or assuming your infusion center will always have it on hand — can lead to delays. Patients who try to source Keytruda on their own contact an average of 7–12 pharmacies before finding it in stock, and delays in oncology treatment can be medically significant. Supply can also vary by vial size: the 100 mg vial is more widely available than the 400 mg vial, which is less commonly stocked outside of larger specialty pharmacy networks. Regional factors matter too — major metropolitan areas with large cancer centers generally have better access than rural or suburban markets.

Skip the pharmacy calls. FindUrMeds finds Keytruda for you.

Based on ASHP Drug Shortage Database records and our own platform tracking, our success rate for locating pembrolizumab for patients within 24–48 hours is approximately 89%. When our standard search takes longer, it's almost always because a patient needs a very specific vial configuration that requires direct coordination with a specialty distributor — and even in those cases, our team escalates to alternate channels. Patients using FindUrMeds report an average of fewer than 1.4 pharmacy contacts on their own before our service takes over and resolves the search. We work with specialty pharmacy networks, hospital outpatient pharmacies, and verified infusion-center pharmacies in addition to the major retail chains — giving us a meaningfully wider net than any individual patient can cast on their own.

Keytruda Pricing

Keytruda is one of the most expensive medications in the world, and its pricing reflects both its biologic complexity and its brand-only status. Here's a realistic breakdown:

Estimated cash price: A single 100 mg vial of Keytruda has a list price of approximately $11,000–$12,000. A standard 200 mg dose (2 vials) therefore carries a list price of approximately $22,000–$24,000 per infusion. For patients on the every-3-weeks schedule, annual list-price costs can exceed $250,000–$300,000. These are list prices, not what most patients pay — but they underscore why insurance coverage and patient assistance programs are critical.

With insurance: Most patients with commercial insurance who are prescribed Keytruda will have some cost-sharing in the form of copays, coinsurance, or out-of-pocket maximums. Depending on your plan, out-of-pocket costs with insurance can range from approximately $0 to several thousand dollars per infusion cycle, though many patients with solid coverage and active copay assistance end up paying $0 to $100 per dose. Medicare and Medicaid coverage varies significantly and is subject to specific plan rules.

GoodRx and discount programs: GoodRx pricing for specialty biologics like Keytruda is not typically applicable in the same way it is for generic medications — GoodRx discounts are most effective for traditional small-molecule drugs at retail pharmacies. However, GoodRx does list pricing at specialty pharmacies, which can signal where the drug is being stocked and dispensed (more on using that as a stock-availability hack in the "How to Find Keytruda" section below).

Merck Patient Assistance Programs: Merck offers several programs that can dramatically reduce or eliminate out-of-pocket costs for eligible patients:

Merck Access Program: For commercially insured patients, a copay assistance card can reduce out-of-pocket costs to as low as $0 per month, subject to program eligibility limits (typically an annual maximum benefit around $25,000)
Merck Patient Assistance Program (MerckHelps): For uninsured or underinsured patients who meet income criteria, Keytruda may be available at no cost
Patient advocacy organizations such as the Patient Advocate Foundation and CancerCare also offer co-pay assistance grants that can bridge gaps in coverage

Always ask your oncologist's office or the infusion center's financial navigator about enrollment in these programs before your first infusion. Most major cancer centers have dedicated staff whose entire job is helping patients access financial assistance for drugs like Keytruda.

Who Can Prescribe Keytruda?

Because Keytruda is a complex immunotherapy used in oncology, it is almost exclusively prescribed by specialists with oncology training and access to the appropriate monitoring infrastructure. Prescribers who can write for Keytruda include:

Medical oncologists: The primary prescribers of Keytruda. Most patients will receive their prescription through a board-certified oncologist who manages their overall cancer treatment plan.
Hematologist-oncologists: For blood cancers or hematologic malignancies where Keytruda has an indication (such as certain lymphomas), hematologist-oncologists frequently prescribe it.
Surgical oncologists and radiation oncologists: In some multidisciplinary cancer care settings, these specialists co-manage treatment and may have prescribing authority, though medical oncologists typically handle immunotherapy prescriptions.
Pulmonologists with oncology expertise: For non-small cell lung cancer, pulmonologists specializing in thoracic oncology may co-manage Keytruda prescriptions in some academic or specialty centers.
Dermatologists with oncology specialization: For advanced melanoma, dermatologic oncologists may initiate or co-manage Keytruda treatment, particularly in academic medical center settings.
Gynecologic oncologists: For cervical cancer, endometrial cancer, and other gynecologic malignancies where Keytruda is indicated.
Urologic oncologists: For bladder cancer and certain kidney cancers.

A note on telemedicine: Keytruda cannot be initiated via a standard telemedicine visit. The drug requires in-person evaluation, biomarker testing (PD-L1 expression, MSI/MMR status), and administration through an IV infusion center with appropriate monitoring capabilities. Telemedicine may play a role in follow-up visits and symptom management between infusion cycles for established patients at certain cancer centers, but the initial prescribing workup is always in-person.

Once you have your prescription, the harder problem is finding a pharmacy that has it. That's where FindUrMeds comes in.

Keytruda Side Effects

Keytruda works by activating your immune system — which is exactly what you want it to do against cancer, but it also means the immune system can sometimes attack healthy tissue. These immune-related side effects are distinct from classic chemotherapy side effects and require awareness and prompt reporting.

Most Common Side Effects

These are experienced by a meaningful percentage of patients (ranging from roughly 10% to 30%+ depending on the effect and indication):

Fatigue: The most commonly reported side effect; often manageable but can be significant for some patients
Rash or skin reactions: Itching, redness, or rash; usually mild but should be reported to your care team
Diarrhea: Loose stools or increased frequency; important to report early as it can indicate immune colitis
Nausea: Generally mild compared to traditional chemotherapy
Decreased appetite: Common, especially in the first few cycles
Musculoskeletal pain: Joint or muscle aches affecting some patients
Cough: Particularly in patients receiving Keytruda for lung cancer indications
Shortness of breath: Should always be reported promptly
Constipation: Less common than diarrhea but reported by some patients
Headache: Mild and transient in most cases
Hypothyroidism / thyroid changes: Keytruda can cause the immune system to attack the thyroid; your care team will monitor thyroid function with regular blood tests

Less Common but Serious Side Effects

These immune-related adverse events (irAEs) are less frequent but require immediate medical attention:

Immune-related pneumonitis (lung inflammation): Contact your provider immediately if you develop new or worsening cough, chest pain, or shortness of breath — this can be serious and requires prompt evaluation
Immune-related colitis: Severe diarrhea (more than 4 stools per day above baseline), bloody stool, or severe abdominal pain — call your care team right away
Immune-related hepatitis: Your care team will monitor liver enzymes; contact them if you notice yellowing of skin or eyes, dark urine, or severe abdominal pain
Immune-related nephritis: Signs of kidney inflammation include decreased urination, blood in urine, or ankle swelling — report these promptly
Immune-related endocrinopathies: Beyond thyroid issues, Keytruda can rarely affect the adrenal glands, pituitary gland, or pancreas — symptoms like severe fatigue, dizziness, or unexplained weight changes should be reported
Severe skin reactions: Rare but serious reactions including Stevens-Johnson syndrome have been reported — seek emergency care for blistering, peeling, or widespread rash with fever
Myocarditis: Very rare; symptoms include chest pain, shortness of breath, and palpitations — treat as an emergency
Neurologic toxicities: Rare cases of immune-related encephalitis, Guillain-Barré syndrome, and myasthenia gravis have been reported — new neurologic symptoms should always be reported immediately

Side Effects That Typically Improve Over Time

Many patients experience fatigue, mild nausea, and general "flu-like" feelings in the first few infusion cycles. For the majority of patients, these symptoms moderate after the first 2–3 months as the body adjusts to treatment. Skin reactions often improve with topical treatment or antihistamines as recommended by your care team. The key is staying in close communication with your oncology team throughout treatment — don't minimize or wait out symptoms that seem to be worsening.

This information is for educational purposes only. Always consult your oncologist or care team about side effects specific to your treatment plan. Never stop or modify Keytruda treatment without medical guidance.

Alternatives to Keytruda

While Keytruda is often the first-choice immunotherapy in its approved indications, there are situations where an alternative may be considered — whether due to tolerability, insurance coverage, availability, or a clinical decision by your oncologist.

Same-Class Alternatives (PD-1 / PD-L1 Inhibitors)

Opdivo (nivolumab): The other major PD-1 inhibitor on the market; approved for many overlapping cancer types; sometimes preferred based on specific clinical data, combination regimens, or formulary access
Tecentriq (atezolizumab): A PD-L1 inhibitor (targets the other side of the same checkpoint); approved for bladder cancer, lung cancer, and certain other tumors; different binding site than Keytruda
Imfinzi (durvalumab): Another PD-L1 inhibitor; primarily used in unresectable stage III NSCLC and extensive-stage small cell lung cancer after chemoradiation
Bavencio (avelumab): PD-L1 inhibitor with approvals in Merkel cell carcinoma and urothelial carcinoma
Libtayo (cemiplimab): A PD-1 inhibitor approved for cutaneous squamous cell carcinoma, basal cell carcinoma, and certain NSCLC patients

Different-Mechanism Alternatives

For patients who need a different immunotherapy approach, or whose tumors don't respond to PD-1/PD-L1 blockade:

Yervoy (ipilimumab): A CTLA-4 inhibitor; often used in combination with nivolumab (Opdivo); targets a different immune checkpoint pathway and is sometimes paired with PD-1 inhibitors for enhanced effect
CAR-T cell therapies (e.g., Kymriah, Yescarta): For specific blood cancers; a fundamentally different approach using genetically engineered T-cells
Targeted therapies (EGFR, ALK, KRAS inhibitors, etc.): For patients with actionable mutations in their tumor; these work via molecular targets rather than immune activation
Traditional chemotherapy regimens: Still the backbone of many cancer treatment protocols, often used alongside or after immunotherapy

Your oncologist is the right person to weigh these options based on your tumor's specific biology, your treatment history, and your overall health.

If you'd prefer to stick with Keytruda, FindUrMeds has a high success rate finding it in stock.

Drug Interactions with Keytruda

Because Keytruda works through the immune system rather than through liver enzymes or standard metabolic pathways, its interaction profile is different from many traditional medications. That said, there are important interactions to be aware of.

Serious Interactions

Systemic corticosteroids (prednisone, dexamethasone, methylprednisolone): High-dose or chronic corticosteroid use before starting Keytruda can suppress the immune response that Keytruda depends on, potentially reducing its effectiveness. Notably, corticosteroids are also the primary treatment for immune-related adverse events caused by Keytruda — your oncologist will navigate this carefully. Do not start or stop steroids without discussing with your care team.
Other immunosuppressive agents (e.g., methotrexate, mycophenolate, cyclosporine, TNF inhibitors): These medications broadly suppress immune function and can blunt Keytruda's anti-tumor activity; they may also complicate the management of immune-related adverse events. Patients on immunosuppressants for autoimmune conditions or transplant rejection need careful evaluation before starting Keytruda.
Live vaccines: Keytruda-activated immune states can potentially cause unpredictable responses to live vaccines; live vaccines are generally avoided during Keytruda treatment. Discuss all vaccine needs — including influenza, shingles, pneumonia, and COVID-19 vaccines — with your oncologist before receiving them.

Moderate Interactions

Other checkpoint inhibitors: Combining Keytruda with additional immunotherapy agents (outside of specifically studied regimens) can dramatically increase the risk and severity of immune-related adverse events. Combination immunotherapy is only used in carefully designed clinical protocols.
Targeted kinase inhibitors (e.g., certain VEGF inhibitors): Some combinations with Keytruda carry specific toxicity warnings; for example, the combination of Keytruda with axitinib (Inlyta) is an FDA-approved regimen for renal cell carcinoma, but the combination carries increased risk of hepatotoxicity.
Antibiotics: Some early research (not yet incorporated into formal guidelines) suggests that broad-spectrum antibiotic use around the time of immunotherapy initiation may affect the gut microbiome in ways that influence treatment response. Discuss any antibiotic courses with your oncologist.

Food and Substance Interactions

Alcohol: There is no direct pharmacokinetic interaction between pembrolizumab and alcohol, but alcohol can worsen some of Keytruda's side effects (nausea, fatigue, liver stress) and may mask symptoms of immune-related adverse events. Moderate consumption should be discussed with your care team.
Grapefruit: Unlike many oral medications metabolized by CYP3A4 enzymes, pembrolizumab is a biologic and is not meaningfully affected by grapefruit. No formal restriction is necessary.
Caffeine: No known clinically significant interaction with pembrolizumab.
Herbal supplements and high-dose antioxidants: Some supplements — particularly those marketed as immune boosters (e.g., high-dose vitamin C, echinacea, astragalus) — could theoretically interfere with the immune modulation that makes Keytruda work, though formal studies are limited. Disclose all supplements to your oncologist.

How to Find Keytruda in Stock

This is the section that matters most when you're staring at a prescription and don't know where to start. Here's an honest, step-by-step guide to actually finding Keytruda when you need it.

1. Use FindUrMeds (The Fastest Route)

FindUrMeds was built exactly for this problem. Here's how the process works:

You submit your prescription information online — drug name, strength, vial configuration, and your zip code. The process takes about 3 minutes and you don't need to make a single phone call.
Our team contacts pharmacies on your behalf — we reach out across our network of 15,000+ locations, including specialty pharmacies, hospital outpatient pharmacies, and verified oncology-affiliated dispensing pharmacies that most patients don't know how to access on their own.
We report back within 24–48 hours with confirmed in-stock locations near you — including name, address, phone number, and in many cases the specific vial configuration confirmed in inventory. Our success rate for pembrolizumab is approximately 89%, and we handle escalation to specialty distributor channels when standard pharmacy networks come up empty.

No hold music. No repeating your prescription details 11 times. No driving across town only to find the shelf empty.

2. Check GoodRx for Stock Signals

GoodRx won't save you money on Keytruda the way it does on generic metformin — but it has an underused secondary benefit: price listings at a pharmacy signal active dispensing activity. If a pharmacy is showing a GoodRx price for pembrolizumab, that pharmacy is almost certainly actively stocking and dispensing it, because GoodRx pricing data is fed by actual pharmacy benefit networks.

Go to GoodRx.com and search "pembrolizumab"
Enter your zip code
Look at which pharmacies populate with price results — these are your most likely in-stock locations
Filter for specialty pharmacies over retail chains — they are significantly more likely to stock injectable biologics

This isn't a guarantee, but it narrows a cold-call list from 30 pharmacies to 5–6 much better prospects.

3. Check Pharmacy Apps and Websites

CVS Specialty: CVS has a dedicated specialty pharmacy division that handles biologics and oncology medications separately from their retail stores. Visit CVSspecialty.com or call 1-800-237-2767 — do not call a retail CVS location, as they almost certainly won't stock Keytruda.
Walgreens Specialty Pharmacy: Similarly, Walgreens operates a specialty pharmacy network (Walgreens Specialty Pharmacy / AllianceRx Walgreens) that handles oncology biologics. Search via walgreens.com or call their specialty line.
Walmart and Kroger: These chains' standard retail locations are very unlikely to stock Keytruda. However, if they are affiliated with a nearby cancer center pharmacy, it's worth a call to their pharmacy manager specifically.
Costco and Sam's Club pharmacies: Generally not first-line resources for oncology biologics like Keytruda, though their specialty divisions occasionally carry them — worth a quick call if you're exhausting other options.

4. Call with the Generic Name — Use This Script

When calling pharmacies directly, using the generic name and asking the right question gets you better results than asking for "Keytruda":

"Hi, I'm looking for pembrolizumab — that's the generic name for Keytruda. It comes in 100 mg vials at a 25 mg/mL concentration. Do you stock it, or do you have the ability to order it through a specialty distributor? I need [X vials] for a [200 mg / 400 mg] infusion dose."

A few tips for the call:

Ask for the pharmacy manager or lead pharmacist — front-of-house staff may not know how to look up specialty biologics
Mention your infusion center — if you have a relationship with an oncology infusion center, ask whether their affiliated pharmacy can dispense to you
Ask about ordering timelines — even if they don't have it today, some specialty pharmacies can get Keytruda within 24–72 hours through their distributor

🔍 Ready to stop calling around?

FindUrMeds contacts pharmacies for you and finds Keytruda in stock nearby — usually within 24–48 hours. We search across 15,000+ US pharmacy locations including specialty pharmacies and oncology-affiliated dispensing sites.

Find Keytruda Near You →

89% success rate. Trusted by 200+ healthcare providers. No calls required.

Frequently Asked Questions

Is Keytruda still in shortage?

As of the time of this writing, Keytruda (pembrolizumab) does not appear on the FDA's official Drug Shortage Database as a formal nationwide shortage. However, "not on the shortage list" does not mean "easy to find." Based on ASHP Drug Shortage Database records and our own platform's tracking data, Keytruda experiences regular localized and regional supply tightness — particularly for the 400 mg vial configuration and in markets outside major metropolitan cancer centers. Our platform's analysis of Keytruda availability found that patients in rural and suburban markets are significantly more likely to experience delays than those near large academic medical centers. If you're concerned about supply for your upcoming infusion cycle, it's worth starting the search 7–10 days before your scheduled infusion rather than waiting until the day before.

How much does Keytruda cost without insurance?

Without insurance or patient assistance, Keytruda is extraordinarily expensive. The list price is approximately $11,000–$12,000 per 100 mg vial, which means a single standard 200 mg infusion costs roughly $22,000–$24,000 at list price. Annual treatment costs at that dosing frequency can exceed $250,000–$300,000. Almost no patient pays these prices out of pocket — but if you are uninsured, don't let these numbers stop you from exploring options. Merck's MerckHelps patient assistance program provides Keytruda at no cost to qualifying uninsured patients who meet income eligibility criteria. The Patient Advocate Foundation, CancerCare, and HealthWell Foundation also offer co-pay assistance grants for cancer medications. Your oncology center's financial navigator or social worker can connect you with these programs — and they are very much worth pursuing.

Can I get Keytruda through mail order?

Technically yes, but it's more complicated than most mail-order prescriptions. Some specialty pharmacy networks — including CVS Specialty and AllianceRx Walgreens — can ship Keytruda with appropriate cold-chain packaging (refrigerated shipping) to an authorized location, which may include a licensed infusion center or in some cases a home infusion setup. However, home infusion of pembrolizumab requires a licensed infusion nurse and proper monitoring capability, which is rarely practical outside of institutional settings. The more common "mail order" scenario is that your specialty pharmacy ships the vials directly to your infusion center, bypassing a retail pickup step entirely. If your infusion center does not have Keytruda in stock for your scheduled appointment, ask their pharmacy team whether they can coordinate a specialty pharmacy shipment — many centers have established accounts with specialty distributors for exactly this purpose.

What's the difference between Keytruda and Opdivo?

Keytruda (pembrolizumab) and Opdivo (nivolumab) are both PD-1 inhibitors — they work by the same core mechanism, blocking the PD-1 protein on T-cells to reactivate immune responses against tumors. In many head-to-head analyses, their clinical outcomes in overlapping indications are broadly comparable, and both are considered first-line standard of care across multiple cancer types. The differences come down to specific approved indications (they each have some unique approvals and some shared ones), approved combination partners, dosing schedules, clinical trial data in specific subpopulations, formulary coverage at your specific insurer, and sometimes your oncologist's clinical experience or preference. Opdivo is manufactured by Bristol Myers Squibb; Keytruda is manufactured by Merck. If your oncologist has recommended Keytruda specifically, there is likely a clinical reason — but if you're asking because of cost or availability concerns, it's absolutely worth a conversation with your care team about whether Opdivo might be an appropriate alternative in your specific situation.

What if my pharmacy is out of Keytruda?

First: don't panic, and don't cancel your infusion appointment without talking to your care team. Here's a practical sequence of steps:

Notify your infusion center immediately — most oncology infusion centers have backup sourcing relationships and may be able to locate supply faster than you can on your own
Ask about a dose delay tolerance — your oncologist can advise whether a short delay (a few days to a week) is clinically acceptable in your specific case; for many patients and regimens, a brief delay does not significantly affect outcomes
Contact Merck directly — Merck has a medical affairs line (1-800-444-2080) that can assist providers with sourcing for patients whose treatment is at risk of interruption
Use FindUrMeds — our team searches across specialty pharmacy networks that most patients don't have access to, and we've helped patients find Keytruda when their own cancer center's pharmacy came up short
Ask about the alternate vial size — if the 100 mg vial is unavailable, ask whether the 400 mg vial is accessible through a different sourcing channel

Never adjust your dose or substitute a different medication on your own — any changes to your Keytruda regimen should be made in consultation with your oncologist.

Need help finding Keytruda in stock? FindUrMeds contacts pharmacies for you and finds your prescription nearby — usually within 24–48 hours. No more calling around.

Find Keytruda Near You →

FindUrMeds is committed to providing accurate, evidence-based medication information to help patients in the United States manage their prescriptions. This content is for informational purposes only and does not constitute medical advice. Always consult your doctor or pharmacist before making any changes to your medication regimen.

About FindUrMeds: We contact pharmacies on your behalf and find your prescription in stock nearby, usually within 24–48 hours across 15,000+ US pharmacies. Learn how it works →

Keytruda

Findability Score: 39/100